L B Manzato1,2, R B Santos3,4, P M M Filho3,4, G Miotto3,4, A M Bastos3,4, J R Vanzin3,4. 1. From the Department of Interventional Neuroradiology (L.B.M., P.M.M.F., G.M., J.R.V.), Neurology and Neurosurgery Service, Clinicas Hospital of Passo Fundo, Passo Fundo, Rio Grande do Sul, Brazil lbmanzato@hotmail.com. 2. Department of Interventional Neuroradiology (R.B.S., A.M.B.), Beneficente Portuguesa Hospital, Belém, Brazil lbmanzato@hotmail.com. 3. From the Department of Interventional Neuroradiology (L.B.M., P.M.M.F., G.M., J.R.V.), Neurology and Neurosurgery Service, Clinicas Hospital of Passo Fundo, Passo Fundo, Rio Grande do Sul, Brazil. 4. Department of Interventional Neuroradiology (R.B.S., A.M.B.), Beneficente Portuguesa Hospital, Belém, Brazil.
Abstract
BACKGROUND AND PURPOSE: The development of flow diverters has changed the endovascular approach to intracranial aneurysms. On the basis of good results, the indications for flow diverters have expanded to include aneurysms of different shapes, locations, and sizes. The objective of the study was to report on the performance of the Flow Re-Direction Endoluminal Device (FRED) in intracranial aneurysm treatment at early and medium-term follow-up. MATERIALS AND METHODS: This single-arm, multicentric, prospective, observational study assessed aneurysm treatment with the FRED. The primary outcome was complete aneurysm occlusion at 6 and 12 months, and the secondary outcome was to evaluate the safety of the FRED with respect to stroke and death rates. RESULTS: Between June 2016 and August 2018, a total of 100 consecutive patients with 131 aneurysms were treated in 107 procedures. Total occlusion rates were 91% and 95% at 6 and 12 months. There was 1 death, and the total final morbidity rate was 1.8%. The complication rate was 4.6%. CONCLUSIONS: As reported previously, the FRED has proved to be a safe and effective tool, with high occlusion rates. The design of the stent makes it more difficult to perform balloon angioplasty compared with similar devices. A branch arising from the aneurysm sac was found to be a predictor of nonocclusion at 12 months, though larger series are needed to estimate the magnitude of the association.
BACKGROUND AND PURPOSE: The development of flow diverters has changed the endovascular approach to intracranial aneurysms. On the basis of good results, the indications for flow diverters have expanded to include aneurysms of different shapes, locations, and sizes. The objective of the study was to report on the performance of the Flow Re-Direction Endoluminal Device (FRED) in intracranial aneurysm treatment at early and medium-term follow-up. MATERIALS AND METHODS: This single-arm, multicentric, prospective, observational study assessed aneurysm treatment with the FRED. The primary outcome was complete aneurysm occlusion at 6 and 12 months, and the secondary outcome was to evaluate the safety of the FRED with respect to stroke and death rates. RESULTS: Between June 2016 and August 2018, a total of 100 consecutive patients with 131 aneurysms were treated in 107 procedures. Total occlusion rates were 91% and 95% at 6 and 12 months. There was 1 death, and the total final morbidity rate was 1.8%. The complication rate was 4.6%. CONCLUSIONS: As reported previously, the FRED has proved to be a safe and effective tool, with high occlusion rates. The design of the stent makes it more difficult to perform balloon angioplasty compared with similar devices. A branch arising from the aneurysm sac was found to be a predictor of nonocclusion at 12 months, though larger series are needed to estimate the magnitude of the association.
Authors: Tibor Becske; Waleed Brinjikji; Matthew B Potts; David F Kallmes; Maksim Shapiro; Christopher J Moran; Elad I Levy; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Henry H Woo; Demetrius K Lopes; Adnan H Siddiqui; Felipe C Albuquerque; David J Fiorella; Isil Saatci; Saruhan H Cekirge; Aaron L Berez; Daniel J Cher; Zsolt Berentei; Miklós Marosfoi; Peter K Nelson Journal: Neurosurgery Date: 2017-01-01 Impact factor: 4.654
Authors: Tibor Becske; David F Kallmes; Isil Saatci; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Christopher J Moran; Henry H Woo; Demetrius K Lopes; Aaron L Berez; Daniel J Cher; Adnan H Siddiqui; Elad I Levy; Felipe C Albuquerque; David J Fiorella; Zsolt Berentei; Miklós Marosfoi; Saruhan H Cekirge; Peter K Nelson Journal: Radiology Date: 2013-02-15 Impact factor: 11.105
Authors: M A Möhlenbruch; O Kizilkilic; M Killer-Oberpfalzer; F Baltacioglu; C Islak; M Bendszus; S Cekirge; I Saatci; N Kocer Journal: AJNR Am J Neuroradiol Date: 2017-08-10 Impact factor: 3.825
Authors: Felipe Padovani Trivelato; Eduardo Wajnberg; Marco Túlio Salles Rezende; Alexandre Cordeiro Ulhôa; Ronie Leo Piske; Thiago Giansante Abud; Luís Henrique de Castro-Afonso; Carlos Gustavo Coutinho Abath; Guilherme Seizem Nakiri; João Francisco Santoro Araújo; José Laércio Júnior Silva; Renato Tavares Tosello; José Ricardo Vanzin; Luciano Bambini Manzato; Carlos Eduardo Baccin; Bruno Anderson Araújo da Mota; Daniel Giansante Abud Journal: Neurosurgery Date: 2020-07-01 Impact factor: 4.654
Authors: José Manuel Pumar; Alexandra Banguero; Hugo Cuellar; Leopoldo Guimaraens; Javier Masso; Salvador Miralbes; Miguel Blanco-Ulla; Fernando Vazquez-Herrero; Miguel Souto; Miguel Gelabert-Gonzalez Journal: Neurosurgery Date: 2017-10-01 Impact factor: 4.654
Authors: Mario Martínez-Galdámez; Saleh M Lamin; Konstantinos G Lagios; Thomas Liebig; Elisa F Ciceri; Rene Chapot; Luc Stockx; Swarupsinh Chavda; Christoph Kabbasch; Giuseppe Faragò; Hannes Nordmeyer; Thierry Boulanger; Mariangela Piano; Edoardo P Boccardi Journal: J Neurointerv Surg Date: 2018-09-27 Impact factor: 5.836
Authors: Leopoldo Guimaraens; Elio Vivas; Jesus Saldaña; Juan Carlos Llibre; Alberto Gil; Ernest Balaguer; Ana Rodríguez-Campello; Elisa Cuadrado-Godia; Angel Ois Journal: J Neurointerv Surg Date: 2019-10-25 Impact factor: 5.836